SABR radiotherapy, a cutting-edge technique used to deliver highly focused doses of radiation to a very small area of the body, is revolutionising cancer treatment NHS England is already requiring radiotherapy clinics to provide SABR radiotherapy for cancer patients across – England, and this technique is practiced by many centres in Wales, Scotland and Northern Ireland. SABR radiotherapy is currently used for: lung cancers, kidney and adrenal gland cancers, liver cancers, bone metastases, and spinal metastases, with trials underway for other body sites including prostate. This not only affects outcomes, but also helps reduce the number of hospital visits and length of treatment, improving the radiotherapy treatment process and patient comfort.
Overview and Benefits
SABR radiotherapy is known for its high effectiveness and accuracy, with local tumour control rates of 90% can be achievable with millimeter-scale accuracy. SABR is non-invasive, convenient, and improves comfort. SABR uses the latest image guidance technologies to remove tumours, sparing healthy tissues while intensifying the radiation dose to the tumour. Furthermore, a new clinical trial, conducted by TROG Cancer Research, found that SABR produced greater survival rates in early stage inoperable lung cancer patients, compared to conventional radiation treatment. In this trial, 77% of the patients who received SABR treatment survived compared to 59% of those who received conventional radiotherapy. In addition 89% of cancers were controlled two years after SABR treatment, compared to 65% for conventional radiotherapy.
SABR Protocol and the NHS
In June, 2020, NHS England announced the acceleration of SABR to cut the number of hospital visits that potentially vulnerable cancer patients need to make. With the implementation of this acceleration, the NHS required radiotherapy departments to offer SABR treatments for non-small cell lung cancer and those with lung, lymph nodes and non-spine bone oligometastatic disease by April, 2021. In the UK, patients are already benefiting from NHS England’s new SABR acceleration, however there are still very long waiting times for cancer patients in the UK.
MVision AI’s capabilities with SABR
With prolonged waiting times for cancer patients, and NHS England’s new expectations with SABR, an accessible SABR protocol for hospitals throughout the UK is even more necessary. Fortunately, MVision AI has developed the only machine learning system that follows the SABR protocol. Last month, MVision AI made an important announcement: the advanced lung CT model was updated (along with many other updates), following the lung SABR protocol.
“The new lung SABR and MR pelvis model (MR-only) release is a significant milestone to support SBRT and MR Only workflow. I am thankful to our existing partners and the team for delivering this within a short period of time,” said MVision AI’s co-founder and CEO, Mahmudul Hasan.
MVisions lung CT, SABR model follows consensus guidelines, is GDPR compliant, and consistent. In addition, MVision AI’s superior, fully automated 3D organ models can be delivered within minutes, rather than hours of manual work.
As stated by MVisions’ Chief Product Officer, co-founder, and medical physicist, Jarkko Niemelä, “during the pandemic, there has been a growing need for shorter and more efficient radiation therapy. Many lung cancer patient groups can be treated with stereotactic radiotherapy where, instead of conventional 20 to 33 visits, the patient has 3 or 4 treatment fractions. We wanted to support this growing need and developed a SABR Consortium guideline compliant lung CT auto-segmentation model.”
If you are interested in learning more about MVision’s AI segmentation in the UK, please contact our UK & Ireland distributor Xiel Ltd. You can learn more, via the Xiel website or by following Xiel on LinkedIn.
For further details regarding Xiel Ltd:
2 Yelling Mill, Yelling Mill Lane, Shepton Mallet, BA4 4JT
Tel: 01749 372217
Email: info@xiel.co.uk
To stay up-to-date on the latest news and information, visit our website or follow us on LinkedIn.
For more information on our services, contact MVision AI:
c/o Terkko Health Hub, Haartmaninkatu 4, 00290 Helsinki, Finland.
Tel: +358 (0) 40 5489 229
Email: info@mvision.ai
Fore media inquiries:
Tel: +358 40 500 7915
Email: pr@mvision.ai
References
